Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders - A clinicopathological study on 575 patients

Leukemia and Lymphoma

Volumn 46, Issue 5, 2005, Pages 709-715

  Thiele, Juergen ^a   Kvasnicka, Hans Michael ^a   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Bone marrow biopsies; CD34+ progenitor cells; Chronic idiopathic myelofibrosis; Clinical findings

Indexed keywords

CD34 ANTIGEN;

ANEMIA; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; CELL COUNT; CELL RENEWAL; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; OSTEOSCLEROSIS; OUTCOMES RESEARCH; PATHOLOGY; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SPLEEN; SPLENOMEGALY; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; THROMBOCYTHEMIA;

ANTIGENS, CD34; BIOPSY; BONE MARROW CELLS; CHRONIC DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, PHILADELPHIA-NEGATIVE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; RETROSPECTIVE STUDIES;

EID: 20144382423     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500046554     Document Type: Article

References (31)

1. Krause DS, Fackler MJ, Civin CI, May WS. CD34: structure, biology, and clinical utility. Blood 1996;87:1-13.
2. + human hemopoietic progenitor cells from the peripheral blood: enzyme-, carbohydrate- and immunocytochemistry, morphometry, and ultrastructure. Leuk Lymphoma 1995;16:483-491.
3. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 2003;102:1249-1253.
4. Wolf BC, Neiman RS. Hypothesis: splenic filtration and the pathogenesis of extramedullary hematopoiesis in agnogenic myeloid metaplasia. Hematol Pathol 1987;1:77-80.
5. Douay L, Laporte JP, Lefrancois G, Najman A, Dupuy-Montbrun MC, Lopez M, Giarratana MC, Gorin NC. Blood and spleen haematopoiesis in patients with myelofibrosis. Leuk Res 1987;11:725-730.
6. Chervenick PA. Increase in circulating stem cells in patients with myelofibrosis. Blood 1973;41:67-71.
7. Chikkappa G, Carsten AL, Chanana AD, Chandra P, Cronkite EP. Increased granulocytic, erythrocytic, and megakaryocytic progenitors in myelofibrosis with myeloid metaplasia. Am J Hematol 1978;4:121-131.
8. Han ZC, Briere J, Nedellec G, Abragall JF, Sensebe L, Parent D, Guern G. Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis. Eur J Haematol 1988;40:130-135.
9. Partanen S, Ruutu T, Vuopio P. Circulating haematopoietic progenitors in myelofibrosis. Scand J Haematol 1982;29:325-330.
10. Thiele J, Imbert M, Pierre R, Vardiman JW, Brunning RD, Flandrin G. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p 35-38.
11. + cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002;68:189-193.
12. + cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-3255.
13. Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L, Pascutto C, Morra. E, Lazzarino M, Cazzola M. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 2003;88:1123-1129.
14. Le Bousse-Kerdiles MC, Martyre MC. Dual implication of fibrogenetic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann Hematol 1999;68:437-444.
15. + stem cells in chronic myeloproliferative disorders. Histol Histopathol 2002;17: 507-521.
16. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p 39-41.
17. Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Polycythaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. WHO classification of tumours: tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p 32-38.
18. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34:29-39.
19. Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol 1998;11:695-720.
20. Laszlo J. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975;12:409-432.
21. + progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue. Ann Hematol 2002;81:86-89.
22. Andreasson B, Swolin B, Kutti J. Increase of CD34 positive cells in polycythaemia vera. Eur J Haematol 1997;59:171-176.
23. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999;17:2954-2970.
24. Andreasson B, Swolin B, Kutti J. Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2000;64:188-193.
25. + myeloid progenitors: role of marrow stromal, fibroblast, and cytomatrix components. Exp Hematol 1991;19:63-70.
26. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
27. Kvasnicka HM, Thiele J. Bone marrow angiogenesis-methods of quantification and changes evolving in chronic myeloproliferative disorders. Histol Histopathol 2004;19: 1245-1260.
28. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
29. Wolf BC, Neiman RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985;65:803-809.
30. Wang JC, Cheung CP, Ahmed F, Steier W, Tobin MS. Circulating granulocyte and macrophage progenitor cells in primary and secondary myelofibrosis. Br J Haematol 1983;54:301-307.
31. Kvasnicka HM, Thiele J, Regn C, Zankovich R, Diehl V, Fischer R. Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis. Ann Hematol 1999;78: 65-72.